Nimotuzumab biosimilar (El Kendi Pharmaceuticals Manufacturing)

尼妥珠单抗生物类似药 (El Kendi Pharmaceuticals Manufacturing)

Report date: 2026/02/01 20:00:10

Base Information

Drug NameNimotuzumab biosimilar (El Kendi Pharmaceuticals Manufacturing)
Drug Alias Name尼莫妥珠单抗生物仿制药 (El Kendi Pharmaceuticals Manufacturing)尼妥珠单抗生物仿制药 (El Kendi Pharmaceuticals Manufacturing)
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsUterine Cervical Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAlgeria
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEl Kendi Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEl Kendi Pharmaceuticals Manufacturing Company
Active IndicationsN/A
Inactive IndicationsUterine Cervical Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A